Logo image of NTLA

INTELLIA THERAPEUTICS INC (NTLA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NTLA - US45826J1051 - Common Stock

10.38 USD
-0.14 (-1.33%)
Last: 1/9/2026, 8:11:29 PM
10.42 USD
+0.04 (+0.39%)
After Hours: 1/9/2026, 8:11:29 PM
Fundamental Rating

3

NTLA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. NTLA has a great financial health rating, but its profitability evaluates not so good. NTLA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NTLA had negative earnings in the past year.
In the past year NTLA has reported a negative cash flow from operations.
NTLA had negative earnings in each of the past 5 years.
NTLA had a negative operating cash flow in each of the past 5 years.
NTLA Yearly Net Income VS EBIT VS OCF VS FCFNTLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

The Return On Assets of NTLA (-48.18%) is comparable to the rest of the industry.
The Return On Equity of NTLA (-59.57%) is better than 61.32% of its industry peers.
Industry RankSector Rank
ROA -48.18%
ROE -59.57%
ROIC N/A
ROA(3y)-37.25%
ROA(5y)-30.46%
ROE(3y)-47.91%
ROE(5y)-38.99%
ROIC(3y)N/A
ROIC(5y)N/A
NTLA Yearly ROA, ROE, ROICNTLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NTLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NTLA Yearly Profit, Operating, Gross MarginsNTLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

7

2. Health

2.1 Basic Checks

NTLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
NTLA has more shares outstanding than it did 1 year ago.
NTLA has more shares outstanding than it did 5 years ago.
NTLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NTLA Yearly Shares OutstandingNTLA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NTLA Yearly Total Debt VS Total AssetsNTLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -0.65, we must say that NTLA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.65, NTLA perfoms like the industry average, outperforming 57.36% of the companies in the same industry.
There is no outstanding debt for NTLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.65
ROIC/WACCN/A
WACC8.83%
NTLA Yearly LT Debt VS Equity VS FCFNTLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 6.21 indicates that NTLA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 6.21, NTLA is in the better half of the industry, outperforming 63.77% of the companies in the same industry.
A Quick Ratio of 6.21 indicates that NTLA has no problem at all paying its short term obligations.
NTLA has a better Quick ratio (6.21) than 64.91% of its industry peers.
Industry RankSector Rank
Current Ratio 6.21
Quick Ratio 6.21
NTLA Yearly Current Assets VS Current LiabilitesNTLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.51% over the past year.
NTLA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -29.22%.
NTLA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.07% yearly.
EPS 1Y (TTM)21.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.34%
Revenue 1Y (TTM)-29.22%
Revenue growth 3Y20.53%
Revenue growth 5Y6.07%
Sales Q2Q%51.27%

3.2 Future

The Earnings Per Share is expected to grow by 23.23% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 93.97% on average over the next years. This is a very strong growth
EPS Next Y23.01%
EPS Next 2Y13.8%
EPS Next 3Y11.78%
EPS Next 5Y23.23%
Revenue Next Year7.96%
Revenue Next 2Y0.17%
Revenue Next 3Y9.71%
Revenue Next 5Y93.97%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NTLA Yearly Revenue VS EstimatesNTLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
NTLA Yearly EPS VS EstimatesNTLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NTLA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NTLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTLA Price Earnings VS Forward Price EarningsNTLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTLA Per share dataNTLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.8%
EPS Next 3Y11.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NTLA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INTELLIA THERAPEUTICS INC

NASDAQ:NTLA (1/9/2026, 8:11:29 PM)

After market: 10.42 +0.04 (+0.39%)

10.38

-0.14 (-1.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners87.01%
Inst Owner Change0%
Ins Owners1.3%
Ins Owner Change0.36%
Market Cap1.20B
Revenue(TTM)57.53M
Net Income(TTM)-445.81M
Analysts73.55
Price Target22.12 (113.1%)
Short Float %36.73%
Short Ratio5.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.79%
Min EPS beat(2)5.61%
Max EPS beat(2)9.97%
EPS beat(4)4
Avg EPS beat(4)9.46%
Min EPS beat(4)5.61%
Max EPS beat(4)15.91%
EPS beat(8)7
Avg EPS beat(8)5.45%
EPS beat(12)10
Avg EPS beat(12)5.75%
EPS beat(16)11
Avg EPS beat(16)-1.99%
Revenue beat(2)1
Avg Revenue beat(2)1.92%
Min Revenue beat(2)-11.02%
Max Revenue beat(2)14.86%
Revenue beat(4)3
Avg Revenue beat(4)22.26%
Min Revenue beat(4)-11.02%
Max Revenue beat(4)47.93%
Revenue beat(8)5
Avg Revenue beat(8)8.79%
Revenue beat(12)8
Avg Revenue beat(12)8.08%
Revenue beat(16)12
Avg Revenue beat(16)14.96%
PT rev (1m)-1.71%
PT rev (3m)-39.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.74%
EPS NY rev (1m)0%
EPS NY rev (3m)3.64%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)-36.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.9
P/FCF N/A
P/OCF N/A
P/B 1.61
P/tB 1.61
EV/EBITDA N/A
EPS(TTM)-4.27
EYN/A
EPS(NY)-3.7
Fwd EYN/A
FCF(TTM)-3.56
FCFYN/A
OCF(TTM)-3.55
OCFYN/A
SpS0.5
BVpS6.46
TBVpS6.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.18%
ROE -59.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.25%
ROA(5y)-30.46%
ROE(3y)-47.91%
ROE(5y)-38.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.93%
Cap/Sales 3.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.21
Quick Ratio 6.21
Altman-Z -0.65
F-Score4
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)130.37%
Cap/Depr(5y)126.64%
Cap/Sales(3y)24.85%
Cap/Sales(5y)23.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.34%
EPS Next Y23.01%
EPS Next 2Y13.8%
EPS Next 3Y11.78%
EPS Next 5Y23.23%
Revenue 1Y (TTM)-29.22%
Revenue growth 3Y20.53%
Revenue growth 5Y6.07%
Sales Q2Q%51.27%
Revenue Next Year7.96%
Revenue Next 2Y0.17%
Revenue Next 3Y9.71%
Revenue Next 5Y93.97%
EBIT growth 1Y47.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.22%
EBIT Next 3Y6.86%
EBIT Next 5Y8.87%
FCF growth 1Y-1.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.05%
OCF growth 3YN/A
OCF growth 5YN/A

INTELLIA THERAPEUTICS INC / NTLA FAQ

What is the ChartMill fundamental rating of INTELLIA THERAPEUTICS INC (NTLA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NTLA.


Can you provide the valuation status for INTELLIA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to INTELLIA THERAPEUTICS INC (NTLA). This can be considered as Overvalued.


Can you provide the profitability details for INTELLIA THERAPEUTICS INC?

INTELLIA THERAPEUTICS INC (NTLA) has a profitability rating of 1 / 10.